# Table of contents

Prologue, xi  
Preface to the Third Edition, xiii  
About the companion website, xv  
Introduction, 1  

## Part I Prevalence, risks, and prognosis of pulmonary embolism and deep venous thrombosis

1 Pulmonary embolism and deep venous thrombosis at autopsy, 5  
2 Incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients and in emergency departments, 18  
3 Case fatality rate and population mortality rate from pulmonary embolism and deep venous thrombosis, 24  
4 Prognosis in acute pulmonary embolism based on right ventricular enlargement and biochemical markers in stable patients, 31  
5 Prognosis in acute pulmonary embolism based on scoring systems, 43  
6 Pulmonary embolism following deep venous thrombosis and outcome with untreated pulmonary embolism, 49  
7 Resolution of pulmonary embolism, 54  
8 Upper extremity deep venous thrombosis, 61  
9 Thromboembolic disease involving the superior vena cava and brachiocephalic veins, 66  
10 Venous thromboembolic disease in the four seasons, 69  
11 Regional differences in the United States of rates of diagnosis of pulmonary embolism and deep venous thrombosis and mortality from pulmonary embolism, 73  
12 Venous thromboembolism according to age and in the elderly, 78  
13 Pulmonary thromboembolism in infants and children, 95  
14 Venous thromboembolism in men and women, 99  
15 Pulmonary embolism and deep venous thrombosis in blacks and whites, 103  
16 Pulmonary thromboembolism in Asians/Pacific Islanders, 108  
17 Pulmonary thromboembolism in American Indians and Alaskan Natives, 116  
18 Venous thromboembolism in patients with cancer, 118  
19 Venous thromboembolism in patients with heart failure, 128  
20 Obesity as a risk factor in venous thromboembolism, 133  
21 Hypertension, smoking, and cholesterol, 139  
22 Overlap of venous and arterial thrombosis risk factors, 141
23 Venous thromboembolism in patients with ischemic and hemorrhagic stroke, 143
24 Paradoxical embolism, 146
25 Pulmonary embolism and deep venous thrombosis in hospitalized adults with chronic obstructive pulmonary disease, 149
26 Pulmonary embolism and deep venous thrombosis in hospitalized patients with asthma, 156
27 Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease, 158
28 Diabetes mellitus and risk of venous thromboembolism, 162
29 Risk of venous thromboembolism with rheumatoid arthritis, 164
30 Venous thromboembolism with inflammatory bowel disease, 166
31 Venous thromboembolism with chronic liver disease, 168
32 Nephrotic syndrome, 171
33 Human immunodeficiency virus infection, 173
34 Venous thromboembolism in pregnancy, 176
35 Amniotic fluid embolism, 182
36 Air travel as a risk for pulmonary embolism and deep venous thrombosis, 184
37 Estrogen-containing oral contraceptives and venous thromboembolism, 187
38 Estrogen and testosterone in men, 192
39 Tamoxifen, 194
40 Venous thromboembolism following bariatric surgery, 198
41 Hypercoagulable syndrome, 204

Part II Diagnosis of deep venous thrombosis

42 Deep venous thrombosis of the lower extremities: clinical evaluation, 215
43 Clinical scoring system for assessment of deep venous thrombosis, 220
44 Clinical probability score plus single negative ultrasound for exclusion of deep venous thrombosis, 223
45 D-dimer for the exclusion of acute deep venous thrombosis, 225
46 D-dimer combined with clinical probability assessment for exclusion of acute deep venous thrombosis, 234
47 D-dimer and single negative compression ultrasound for exclusion of deep venous thrombosis, 236
48 Contrast venography, 237
49 Compression ultrasound for the diagnosis of deep venous thrombosis, 240
50 Impedance plethysmography and fibrinogen uptake tests for diagnosis of deep venous thrombosis, 247
51 Ascending CT venography and venous phase CT venography for diagnosis of deep venous thrombosis, 250
52 Magnetic resonance venography for diagnosis of deep venous thrombosis, 255
53 P-selectin and microparticles to predict deep venous thrombosis, 260

Part III Diagnosis of acute pulmonary embolism

54 Clinical characteristics of patients with no prior cardiopulmonary disease, 265
55 Relation of right-sided pressures to clinical characteristics of patients with no prior cardiopulmonary disease, 272
56 The history and physical examination in all patients irrespective of prior cardiopulmonary disease, 275
57 Clinical characteristics of patients with acute pulmonary embolism stratified according to their presenting syndromes, 280
58 Clinical assessment in the critically ill, 286
<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>59</td>
<td>The electrocardiogram, 289</td>
</tr>
<tr>
<td>60</td>
<td>The plain chest radiograph, 303</td>
</tr>
<tr>
<td>61</td>
<td>Arterial blood gases and the alveolar–arterial oxygen difference in</td>
</tr>
<tr>
<td></td>
<td>acute pulmonary embolism, 308</td>
</tr>
<tr>
<td>62</td>
<td>Fever in acute pulmonary embolism, 316</td>
</tr>
<tr>
<td>63</td>
<td>Leukocytosis in acute pulmonary embolism, 319</td>
</tr>
<tr>
<td>64</td>
<td>Alveolar dead-space in the diagnosis of pulmonary embolism, 321</td>
</tr>
<tr>
<td>65</td>
<td>Empirical assessment and clinical models for diagnosis of acute</td>
</tr>
<tr>
<td></td>
<td>pulmonary embolism, 324</td>
</tr>
<tr>
<td>66</td>
<td>Prognostic models for pulmonary embolism, 329</td>
</tr>
<tr>
<td>67</td>
<td>D-dimer for the exclusion of acute pulmonary embolism, 335</td>
</tr>
<tr>
<td>68</td>
<td>D-dimer combined with clinical probability for exclusion of acute</td>
</tr>
<tr>
<td></td>
<td>pulmonary embolism, 346</td>
</tr>
<tr>
<td>69</td>
<td>D-dimer in combination with amino-terminal pro-B-type natriuretic</td>
</tr>
<tr>
<td></td>
<td>peptide for exclusion of acute pulmonary embolism, 349</td>
</tr>
<tr>
<td>70</td>
<td>Tissue plasminogen activator, plasminogen activator inhibitor-1, and</td>
</tr>
<tr>
<td></td>
<td>thrombin–antithrombin III complexes in the exclusion of acute</td>
</tr>
<tr>
<td></td>
<td>pulmonary embolism, 350</td>
</tr>
<tr>
<td>71</td>
<td>Echocardiogram in the diagnosis of acute pulmonary embolism, 352</td>
</tr>
<tr>
<td>72</td>
<td>Trends in the use of diagnostic imaging in patients hospitalized with</td>
</tr>
<tr>
<td></td>
<td>acute pulmonary embolism, 356</td>
</tr>
<tr>
<td>73</td>
<td>Techniques of perfusion and ventilation imaging, 358</td>
</tr>
<tr>
<td>74</td>
<td>Ventilation–perfusion lung scan criteria for interpretation prior to</td>
</tr>
<tr>
<td></td>
<td>the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED), 363</td>
</tr>
<tr>
<td>75</td>
<td>Observations from PIOPED: ventilation–perfusion lung scans alone and in combination with clinical assessment, 367</td>
</tr>
<tr>
<td>76</td>
<td>Ventilation–perfusion lung scans according to complexity of lung disease, 374</td>
</tr>
<tr>
<td>77</td>
<td>Perfusion lung scans alone in acute pulmonary embolism, 376</td>
</tr>
<tr>
<td>78</td>
<td>Probability interpretation of ventilation–perfusion lung scans in relation to the largest pulmonary arterial branches in which pulmonary embolism is observed, 379</td>
</tr>
<tr>
<td>79</td>
<td>Revised criteria for evaluation of lung scans recommended by nuclear physicians in PIOPED, 381</td>
</tr>
<tr>
<td>80</td>
<td>Criteria for very-low-probability interpretation of ventilation–perfusion lung scans, 385</td>
</tr>
<tr>
<td>81</td>
<td>Probability assessment based on the number of mismatched segmental equivalent perfusion defects, 391</td>
</tr>
<tr>
<td>82</td>
<td>Probability assessment based on the number of mismatched vascular defects and stratification according to prior cardiopulmonary disease, 395</td>
</tr>
<tr>
<td>83</td>
<td>The addition of clinical assessment to stratification according to prior cardiopulmonary disease further optimizes the interpretation of ventilation–perfusion lung scans, 401</td>
</tr>
<tr>
<td>84</td>
<td>Pulmonary scintigraphy scans since PIOPED, 407</td>
</tr>
<tr>
<td>85</td>
<td>Single photon emission computed tomographic (SPECT) lung scans, 412</td>
</tr>
<tr>
<td>86</td>
<td>SPECT with radiolabeled markers, 426</td>
</tr>
<tr>
<td>87</td>
<td>Standard and augmented techniques in pulmonary angiography, 427</td>
</tr>
<tr>
<td>88</td>
<td>Subsegmental pulmonary embolism, 435</td>
</tr>
<tr>
<td>89</td>
<td>Quantification of pulmonary embolism by conventional and CT angiography, 440</td>
</tr>
<tr>
<td>90</td>
<td>Complications of pulmonary angiography, 442</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>91 Contrast-enhanced spiral CT for the diagnosis of acute pulmonary</td>
<td>446</td>
</tr>
<tr>
<td>embolism before the Prospective Investigation of Pulmonary Embolism</td>
<td></td>
</tr>
<tr>
<td>Diagnosis II</td>
<td></td>
</tr>
<tr>
<td>92 Methods of PIOPED II</td>
<td>458</td>
</tr>
<tr>
<td>93 Multidetector spiral CT of the chest for acute pulmonary embolism:</td>
<td>467</td>
</tr>
<tr>
<td>results of the PIOPED II trial</td>
<td></td>
</tr>
<tr>
<td>94 Multidetector CT pulmonary angiography since PIOPED II</td>
<td>473</td>
</tr>
<tr>
<td>95 Outcome studies of pulmonary embolism versus accuracy</td>
<td>478</td>
</tr>
<tr>
<td>96 Contrast-induced nephropathy</td>
<td>480</td>
</tr>
<tr>
<td>97 Radiation exposure and risk</td>
<td>483</td>
</tr>
<tr>
<td>98 Magnetic resonance angiography for the diagnosis of acute</td>
<td>490</td>
</tr>
<tr>
<td>pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td>99 Serial noninvasive leg tests in patients with suspected pulmonary</td>
<td>499</td>
</tr>
<tr>
<td>embolism</td>
<td></td>
</tr>
<tr>
<td>100 Diagnosis of pulmonary embolism in the coronary care unit</td>
<td>501</td>
</tr>
<tr>
<td>101 Silent pulmonary embolism with deep venous thrombosis</td>
<td>506</td>
</tr>
<tr>
<td>102 Fat embolism syndrome</td>
<td>511</td>
</tr>
<tr>
<td>103 Diagnostic approach to acute pulmonary embolism</td>
<td>516</td>
</tr>
<tr>
<td>104 Warfarin and other vitamin K antagonists</td>
<td>523</td>
</tr>
<tr>
<td>105 Unfractionated heparin, low-molecular-weight heparin,</td>
<td>531</td>
</tr>
<tr>
<td>heparinoid, and pentasaccharide</td>
<td></td>
</tr>
<tr>
<td>106 Parenteral inhibitors of factors Va, VIIIa, tissue factor, and</td>
<td>540</td>
</tr>
<tr>
<td>thrombin</td>
<td></td>
</tr>
<tr>
<td>107 Novel oral anticoagulants</td>
<td>545</td>
</tr>
<tr>
<td>108 Aspirin for venous thromboembolism</td>
<td>552</td>
</tr>
<tr>
<td>109 Immediate therapeutic levels of heparin in relation to timing of</td>
<td>555</td>
</tr>
<tr>
<td>recurrent events</td>
<td></td>
</tr>
<tr>
<td>110 Intermittent pneumatic compression</td>
<td>558</td>
</tr>
<tr>
<td>111 Graduated compression stockings</td>
<td>561</td>
</tr>
<tr>
<td>112 Ankle exercise and venous blood velocity</td>
<td>565</td>
</tr>
<tr>
<td>113 Thrombolytic therapy for deep venous thrombosis</td>
<td>567</td>
</tr>
<tr>
<td>114 Mechanical and ultrasonic enhancement of catheter-directed</td>
<td>572</td>
</tr>
<tr>
<td>thrombolytic therapy for deep venous thrombosis</td>
<td></td>
</tr>
<tr>
<td>115 Thrombolytic therapy for treatment of acute pulmonary embolism</td>
<td>574</td>
</tr>
<tr>
<td>116 Catheter-tip embolectomy in the management of acute massive</td>
<td>589</td>
</tr>
<tr>
<td>pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td>117 Vena cava filters</td>
<td>597</td>
</tr>
<tr>
<td>118 Withholding treatment of patients with acute pulmonary embolism</td>
<td>615</td>
</tr>
<tr>
<td>who have a high risk of bleeding provided and negative serial</td>
<td></td>
</tr>
<tr>
<td>noninvasive leg tests</td>
<td></td>
</tr>
<tr>
<td>119 Home treatment of deep venous thrombosis</td>
<td>617</td>
</tr>
<tr>
<td>120 Home treatment of acute pulmonary embolism</td>
<td>622</td>
</tr>
<tr>
<td>121 Pulmonary embolectomy</td>
<td>626</td>
</tr>
<tr>
<td>122 Chronic thromboembolic pulmonary hypertension and</td>
<td>634</td>
</tr>
<tr>
<td>pulmonary thromboendarterectomy</td>
<td></td>
</tr>
<tr>
<td>123 Prevention and treatment of deep venous thrombosis and acute</td>
<td>639</td>
</tr>
<tr>
<td>pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td>Part IV Prevention and treatment of deep venous thrombosis and</td>
<td></td>
</tr>
<tr>
<td>pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td>Index</td>
<td>647</td>
</tr>
</tbody>
</table>